Wang Qianfei
Professor
Beijing Institute of Genomics
Chinese Academy of Sciences
China
Biography
Dr. WANG Qianfei "Jeffrey" is currently a professor and principal investigator at Beijing Institute of Genomics (BIG), Chinese Academy of Sciences (CAS). He is also a joint professor at the State Key Laboratory of Experimental Hematology and a member of the 13th and 14th expert committee in Medical Sciences of National Natural Science Foundation of China. He was awarded the National Science Fund for Distinguished Young Scholars in 2014. Dr. WANG received his bachelor degree in clinical medicine from Shandong Medical University in China. He then earned his Ph.D. from Johns Hopkins University School of Medicine in 2002 (thesis advisors: Drs. Mark Schlissel and Alan Friedman). Under the supervision of Dr. Edward Rubin, Dr. WANG pursued his postdoctoral training in the Genomics Division at Lawrence Berkeley National Laboratory, University of California, Berkeley. Before Dr. WANG joined the faculty at Beijing Institute of Genomics, he was an Assistant Professor (Research Associate) at Section of Hematology/Oncology, the University of Chicago (2007-2009). Dr. WANG's background in clinical medicine, experimental biology and genomics has provided him with a unique opportunity to decipher the molecular mechanism and regulatory network controlling hematopoiesis and the development of human leukemia.
Research Interest
Leukemia is a malignant disease characterized by the uncontrolled accumulation of blood cells. Leukemia causes more deaths than any other cancer among children and young adults under the age of 20. Despite multi agent chemotherapy and stem cell transplantation, the overall survival rate of acute myeloid leukemia is less than 30%. Through integrative programs combining biochemistry, cellular/molecular biology, and powerful genomics technology platforms, we seeks to transform original raw genomics data and basic research insights into knowledges of precision medicine related to AML diagnosis and treatment. Our lab has employed a combined genomic and functional characterization strategy to: 1) explore the functional and clinical relevance of newly discovered genomic aberrations in acute leukemia; 2) identify key genes/pathways critical for drug resistance in chemotherapy; 3) define genomic signatures for the classification of responders in AML drug treatment.
Publications
-
Zheng M, Lin FL, Hou FX, Li GL, Zhu CY, Xu PY, Xing CH*, Wang QF*. Association between Promoter Methylation of Gene ERCC3 and Benzene Hematotoxicity. Int. J. Environ. Res. Public Health. 14(8):921,2017
-
Huang L, Liu D, Wang N, Ling SP, Tang YT, Wu J, Hao LT, Luo H, Hu XL, Sheng LS, Zhu LJ, Wang D, Luo Y, Shang Z, Xiao M, Mao X, Zhou KG, Cao LH, Dong LL, Zheng XC, Sui PP, He JL, Mo SL, Yan J, Ao QL, Qiu LG, Zhou HS, Liu QF, Zhang HY, Li JY, Jin J, Fu L, Zhao WL, Chen JP, Du X, Qing GL, Liu HD, Liu X, Huang G, Ma D, Zhou JF*, Wang QF*. Integrated Genomic Analysis Identifies Deregulated JAK/STAT-MYC-Biosynthesis Axis in Aggressive NK-cell Leukemia.Cell Research. 2017 (Accepted)
-
Li YY, Jin C, Bai H, Gao YX, Sun S, Chen L, Qin L, Liu PP, Cheng LZ*, Wang QF*. Human NOTCH4 is a key target of RUNX1 in megakaryocytic differentiation. Blood. 2017 (Accepted)
